Industry structure and developments
The Companys sales decreased compared to the previous year, primarily due to delays in the license renewal process in Sri Lanka. The renewal process impacted our ability to operate at full capacity, which in turn affected revenue generation during the reporting period.
Risks and concerns
The Board recognizes that reliance on timely regulatory approvals in key markets presents an operational risk. Any recurrence of such delays, in Sri Lanka could lead to extended disruptions, reduced revenue,
Internal control systems and their adequacy The internal control systems are adequate to the size and nature of operations of the company.
Outlook
Our Company continues to have cordial relations with its employees and other stakeholders.
Key Financial Ratios: Refer Notes on accounts
DISCLOSURE OF ACCOUNTING TREATMENT:
The Company has complied with the appropriate accounting policies and has ensured that they have been applied consistently. There have been no deviations from the treatment prescribed in the Accounting Standards notified under Section 133 of the Companies Act, 2013.
For and on behalf of the Board of Directors | |
Hindustan Bio Sciences Limited | |
Sd/- | |
Venkata Rama Mohan Raju Jampana | |
Place: Hyderabad |
Managing Director |
Date:31-07-2025 |
(DIN: 00060800) |
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.